Xiongxiong LU

Xiongxiong LU


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2021 in Human Cell
Verified
Journal Article
Closed access
PDF file
JXJing Xie
Jing Xie
SXShen Xing
Shen Xing
BSBo-Yong Shen
Bo-Yong Shen
HCHai-Tao Chen
Hai-Tao Chen
BSBin Sun
Bin Sun
XLXiongxiong LU
Xiongxiong LU

1 June 2022 in International Journal of Surgery
Verified
Journal Article
Closed access
ZSZiyun Shen
Ziyun Shen
HCHaoda Chen
Haoda Chen
WWWeishen Wang
Weishen Wang
WXWei Xu
Wei Xu
YZYiran Zhou
Yiran Zhou
BSBaiyong Shen
Baiyong Shen
Clinically relevant postoperative pancreatic fistula (CR-POPF) remains the major cause of morbidity following pancreaticoduodenectomy (PD). Several model score systems such as the Fistula Risk Score (FRS) have been developed to predict CR-POPF using preoperative and intraoperative data. Machine learning (ML) algorithms are increasingly applied in the medical field and they could be used to assess the risk of CR-POPF, identify clinically meaningful data and guide drain removal. Data from consecutive patients who underwent PD between January 1, 2010 and March 31, 2021 at a single high-volume center was collected retrospectively in this study. Demographics, clinical features, intraoperative parameters, and laboratory values were used to conduct the ML model. Four different ML algorithms (CatBoost, lightGBM, XGBoost and Random Forest) were used to train this model with cross-validation. A total of 2421 patients with 62 clinical parameters were enrolled in this ML model. The majority of patients (76.3%) underwent open PD while others underwent robot-assisted PD. CR-POPF occurred in 424 (17.5%) patients. The CatBoost algorithm outperformed other algorithms with a mean area under the receiver operating characteristic curve (AUC) of 0.81 (95% confidence interval: 0.80-0.82) from the 5-fold cross-validation procedure. In the test dataset, the CatBoost algorithm also achieved the best mean-AUC of 0.83. The most important value was mean drain fluid amylase (DFA) in the first seven postoperative days (POD). The performance of models that used only preoperative data and intraoperative data was marginally lower than that of models that used combined data. Our ML algorithms could be applied as early diagnostic tools for CR-POPF in patients who underwent PD. Such real-time clinical decision support tools can identify patients with a high risk of CR-POPF, help in developing the perioperative management plan and guide the optimal timing of drain removal.

19 July 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
LCLong Chen
Long Chen
JZJing Zhang
Jing Zhang
XWXinjing Wang
Xinjing Wang
YLYu Li
Yu Li
LZLu Zhou
Lu Zhou
CSChunquan Sheng
Chunquan Sheng
KRAS‒PDEδ interaction is revealed as a promising target for suppressing the function of mutant KRAS. The bottleneck in clinical development of PDEδ inhibitors is the poor antitumor activity of known chemotypes. Here, we identified novel spiro-cyclic PDEδ inhibitors with potent antitumor activity both in vitro and in vivo. In particular, compound 36l (KD = 127 ± 16 nmol/L) effectively bound to PDEδ and interfered with KRAS–PDEδ interaction. It influenced the distribution of KRAS in Mia PaCa-2 cells, downregulated the phosphorylation of t-ERK and t-AKT and promoted apoptosis of the cells. The novel inhibitor 36l exhibited significant in vivo antitumor potency in pancreatic cancer patient-derived xenograft (PDX) models. It represents a promising lead compound for investigating the druggability of KRAS‒PDEδ interaction.

1 April 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YJYangbing Jin
Yangbing Jin
YWYuanchi Weng
Yuanchi Weng
YWYue Wang
Yue Wang
JLJiewei Lin
Jiewei Lin
XDXiaxing Deng
Xiaxing Deng
XLXiongxiong LU
Xiongxiong LU
Background: Pancreatic cancer is an extremely lethal digestive cancer with late diagnosis and poor prognosis. miR-934 has been reported to serve as an oncogene in multiple cancers, such as ovarian cancer and bladder cancer. However, its role in pancreatic cancer remains undiscovered. Materials and Methods: The expression data of miR-934 were obtained from the Gene Expression Omnibus database and from our own patient samples. The clinicopathological data and corresponding follow-up data were retrieved from The Cancer Genome Atlas database. CCK8 and colony formation assays were conducted to measure cell proliferation capacity in vitro. Wound healing and transwell assays were performed to detect the migration ability of pancreatic cancer cell. Results: We found that miR-934 was significantly upregulated in pancreatic tumor samples and cell lines. The expression of miR-934 was related to pathological stages. Upregulated miR-934 was associated with poor prognosis in patients with pancreatic cancer. Mir-934 inhibition reduced, while overexpression promoted, cell proliferation and migration. Mechanically, we found miR-934 could directly bind to 3ʹ-UTR of PROX1 leading to mRNA derogation. Furthermore, increased cell proliferation and migration caused by miR-934 overexpression could be reversed by forced PROX1 expression. Conclusion: miR-934 is an oncogene in pancreatic cancer and could serve as a prognosis indicator for patients with pancreatic cancer, suggesting that miR-934 is a promising therapeutic target for pancreatic cancer.

13 June 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SZSiyi Zou
Siyi Zou
XWXinjing Wang
Xinjing Wang
HCHaoda Chen
Haoda Chen
JLJiewei Lin
Jiewei Lin
CWChenlei Wen
Chenlei Wen
BSBaiyong Shen
Baiyong Shen
Background: Prognosis for patients recurred rapidly after resection of pancreatic ductal adenocarcinoma (PDAC) was extremely poor. We proposed the concept of postoperative hyper-progression disease (PO-HPD) to define recurrence within 2 months after surgery, explored the role of surgery for postoperative HPD patients and determined the predictive preoperative risk factors and genomic features of PO-HPD. Methods: 976 patients undergoing curative resection of PDAC were enrolled. Survival data of 1733 stage IV patients from the US Surveillance, Epidemiology and End Results database was also collected. Patients relapsed were grouped into 3 groups regarding of the recurrence time (within 2 months were PO-HPD, within 2 to 12 months were early recurrence (ER) and within > 12 months were late recurrence (LR)). Risk factors for PO-HPD were explored with logistic regression models. Genomic features of 113 patients were investigated using next-generation sequencing-based gene panel testing. Results: 718 of 976 cases relapsed, 101were PO-HPD, 418 were ER and 199 were LR. Total survival of PO-HPD was 12.5 months, shorter than that of ER (16.7 months) and LR (35.1 months), and verged on that of stage IV patients (10.6 months). Preoperative risk factors for PO-HPD included red blood cell count < 3.94*10^12/L, CA19–9 ≥ 288.6 U/mL, CA125 ≥ 22.3 U/mL and tumor size≥3.45 cm. Mutations of CEBPA, ATR and JAK1 were only identified in PO-HPD and they owned lower level of CN gain compared to others. Conclusions: Prognosis of PO-HPD was extremely poor and the role of surgery for PO-HPD should be prudently assessed.

10 April 2023 in International Journal of Surgery
Verified
Journal Article
Open access
QZQian Zhan
Qian Zhan
LZLei Zhang
Lei Zhang
CWChenlei Wen
Chenlei Wen
YYYing Yang
Ying Yang
YJYangbing Jin
Yangbing Jin
BSBaiyong Shen
Baiyong Shen
Background: Patients with resected pancreatic adenocarcinoma (PAAD) often experience short-term relapse and dismal survival, suggesting an urgent need to develop predictive and/or prognostic biomarkers for these populations. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients. Materials and Methods: HLA-I (A, B and C) genotyping and somatic variants of 608 Chinese PAAD patients were determined by targeted next-generation sequencing of matched blood cells and tumor tissues. HLA-A/B alleles were classified with the available definition of 12 supertypes. Kaplan-Meier curves of disease-free survival (DFS) and multivariable Cox proportional-hazards regression analyses were performed to determine the survival difference in 226 selected patients with radical resection. Early-stage (I-II) patients constituted the majority (82%, 185/226) and some stage I-II individuals with high-quality tumor samples were analyzed by RNA-sequencing to examine immunophenotypes. Results: Patients with HLA-A02+B62+B44- had significantly shorter DFS (median, 239 vs. 410 d; hazard ratio [HR]=1.65, P=0.0189) than patients without this genotype. Notably, stage I-II patients carrying HLA-A02+B62+B44- had sharply shorter DFS than those without HLA-A02+B62+B44- (median, 237 vs. 427 d; HR=1.85, P=0.007). Multivariate analyses revealed that HLA-A02+B62+B44- was associated with significantly inferior DFS (P=0.014) in stage I-II patients but not in stage III patients. Mechanistically, HLA-A02+B62+B44- patients were associated with a high rate of KRAS G12D & TP53 mutations, lower HLA-A expression, and less inflamed T-cell infiltration. Conclusions: The current results suggest that a specific combination of germline HLA-A02/B62/B44 supertype, HLA-A02+B62+B44-, was a potential predictor for DFS in early-stage PAAD patients after surgery. Export